WordNet

pursue a positive and satisfying existence; "You must accept yourself and others if you really want to live"
actually being performed at the time of hearing or viewing; "a live television program"; "brought to you live from Lincoln Center"; "live entertainment involves performers actually in the physical presence of a live audience" (同)unrecorded
abounding with life and energy; "the club members are a really live bunch"
charged with an explosive; "live ammunition"; "a live bomb"
exerting force or containing energy; "live coals"; "tossed a live cigarette out the window"; "got a shock from a live wire"; "live ore is unmined ore"; "a live bomb"; "a live ball is one in play"
highly reverberant; "a live concert hall"
in current use or ready for use; "live copy is ready to be set in type or already set but not yet proofread"
lead a certain kind of life; live in a certain style; "we had to live frugally after the war"
not recorded; "the opera was broadcast live"
of current relevance; "a live issue"; "still a live option"
true to life; lifelike; "the living image of her mother"
people who are still living; "save your pity for the living"
(informal) absolute; "she is a living doll"; "scared the living daylights out of them"; "beat the living hell out of him"
(used of minerals or stone) in its natural state and place; not mined or quarried; "carved into the living stone";
pertaining to living persons; "within living memory"
still in active use; "a living language"
failing to speak or communicate etc when expected to; "the witness remained silent" (同)silent
secrecy; "mums the word"
immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum
an acute contagious viral disease characterized by fever and by swelling of the parotid glands (同)epidemic_parotitis

PrepTutorEJDIC

『生きている』,生命がある / 《副詞[句]を伴って》〈人などが〉『生き続ける』 / 〈物事が〉長く続く,存続する / 《場所を表す副詞[句]を伴って》〈人などが〉『住む』,居住する / 《副詞[句]を伴って》『生活する』,暮らす / 生人を楽しむ,おもしろく桟らす / 《a+形容詞癌lifeを目的語にして》〈…を生活〉‘を'する / 〈思想など〉‘を'実銭する
《名詞の前にのみ用いて》『生きている』 / 『活気のある』 / (問題などが)当面の / 燃えている / (弾丸などが)まだ爆発してない,未発の / まだ動いている(働いている),有効な / 電流が通じている / (放走が)生の,実況の
『生きている』 / 生活の;生活に適した / 『現存の』,まだ使われている / 『生き生きした』,活気のある / 『生き写しの』 / 〈U〉生存;生活状態,暮らし / 〈U〉《a~,one's~》『生計』,暮らしの費用(livelihood) / 《the~》《複数扱い》生きている人々
《補語にのみ用いて》沈黙した,物を言わない(silent)
=mother(《米》mom)
菊[chrysanthemumの短縮形]
牛痘種,痘苗(牛痘を起こすビールスで,天然痘予防のために人体に接種される) / (伝染病の病原菌から作った)ワクチン
耳下腺(せん),お多福かぜ

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ムンプスウイルスワクチン mumps virus vaccine
2. 小児および思春期における標準的予防接種 standard immunizations for children and adolescents
3. リスクの高い成人に対する麻疹-ムンプス-風疹ワクチン接種 measles mumps rubella vaccination in high risk adults
4. 妊娠中の予防接種 immunizations during pregnancy
5. ムンプスの疫学、臨床症状、診断およびマネージメント epidemiology clinical manifestations diagnosis and management of mumps

English Journal

From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.

Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS.Author information Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.AbstractPatients with moderate to severe psoriasis often require systemic immunomodulatory medications that place them at risk for infection. Vaccination is a proven strategy to reduce infections. However, vaccination rates among patients with inflammatory autoimmune conditions, including psoriasis, remain low. We review the literature regarding vaccine-preventable illness and vaccinations commonly used in the United States in patients older than 18 years on immunosuppressive therapies that are used in the treatment of psoriasis. The medical board of the National Psoriasis Foundation recommends that dermatologists counsel patients on updating vaccinations in accordance with recommendations of the Advisory Committee for Immunization Practices as any measures taken to prevent infection can increase the safety of immunomodulatory therapies.
Journal of the American Academy of Dermatology.J Am Acad Dermatol.2013 Dec;69(6):1003-13. doi: 10.1016/j.jaad.2013.06.046. Epub 2013 Sep 26.
Patients with moderate to severe psoriasis often require systemic immunomodulatory medications that place them at risk for infection. Vaccination is a proven strategy to reduce infections. However, vaccination rates among patients with inflammatory autoimmune conditions, including psoriasis, remain
PMID 24075223

Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children.

Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, Jackson LA, Tse A, Belongia EA, Hambidge SJ, Weintraub E, Baxter R, Klein NP.Author information Kaiser Permanente Vaccine Study Center, Oakland, California.AbstractIMPORTANCE The first dose of live attenuated measles-containing vaccines is associated with an increased risk of febrile seizures 7 to 10 days following immunization among 12- to 23-month-old children. The combination measles, mumps, rubella, and varicella vaccine is associated with a 2-fold increased risk of febrile seizures 7 to 10 days following immunization compared with the separately administered measles, mumps, and rubella and varicella vaccines. It is unknown whether the magnitude of these increased risks depends on age at immunization. OBJECTIVE To examine the potential modifying effect of age on the risk of fever and seizures following immunization with measles-containing vaccines. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study at 8 Vaccine Safety Datalink sites of a total of 840 348 children 12 to 23 months of age who had received a measles-containing vaccine from 2001 through 2011. EXPOSURES Any measles-containing vaccines and measles-containing vaccines by type. MAIN OUTCOMES AND MEASURES Fever and seizure events occurring during a 42-day postimmunization observation period. RESULTS In the analysis of any measles-containing vaccines, the increased risk of seizures during the 7- to 10-day risk interval, using the remainder of the observation period as the control interval, was significantly greater among older children (relative risk, 6.5; 95% CI, 5.3-8.1; attributable risk, 9.5 excess cases per 10 000 doses; 95% CI, 7.6-11.5) than among younger children (relative risk, 3.4; 95% CI, 3.0-3.9; attributable risk = 4.0 excess cases per 10 000 doses; 95% CI, 3.4-4.6). The relative risk of postimmunization fever was significantly greater among older children than among younger children; however, its attributable risk was not. In the analysis of vaccine type, measles, mumps, rubella, and varicella vaccine was associated with a 1.4-fold increase in the risk of fever and 2-fold increase in the risk of seizures compared with measles, mumps, and rubella vaccine administered with or without varicella vaccine in both younger and older children. CONCLUSIONS AND RELEVANCE Measles-containing vaccines are associated with a lower increased risk of seizures when administered at 12 to 15 months of age. Findings of this study that focused on safety outcomes highlight the importance of timely immunization of children with the first dose of measles-containing vaccines.
JAMA pediatrics.JAMA Pediatr.2013 Dec 1;167(12):1111-7. doi: 10.1001/jamapediatrics.2013.2745.
IMPORTANCE The first dose of live attenuated measles-containing vaccines is associated with an increased risk of febrile seizures 7 to 10 days following immunization among 12- to 23-month-old children. The combination measles, mumps, rubella, and varicella vaccine is associated with a 2-fold increas
PMID 24126936

Immunologic characterization of a novel inactivated nasal mumps virus vaccine adjuvanted with Protollin.

Young KR, Nzula S, Burt DS, Ward BJ.Author information Research Institute of the McGill University Health Centre, Department of Infectious Diseases, McGill University, 1650 Cedar Ave., Montreal, Quebec, Canada H3G 1A4. Electronic address: katie.young@mail.mcgill.ca.AbstractAn inactivated, mucosal mumps virus (MuV) vaccine would address many of the problems associated with current live-attenuated formulations. Protollin (Prl)-based adjuvants (containing TLR2 and TLR4 ligands) are well-suited for nasal administration. We sought to develop an inactivated whole-virus nasal vaccine for MuV using the Prl adjuvant/delivery vehicle and to test tolerability and immunogenicity in a mouse model. BALB/c mice exhibited signs of transient reactogenicity (hunched posture, erect fur, weight loss ≤10% of total body weight) following administration of intranasal MuV-Prl vaccines, though most of these manifestations resolved within 24h. Compared to high-dose unadjuvanted vaccine (8μgMuV), administration of high-dose adjuvanted formulation (8μgMuV-Prl) induced greater MuV-specific serum IgG (3.26E6ng/mL vs. 2.2E5ng/mL, 8μgMuV-Prl vs. 8μgMuV, p<0.001) and mucosal IgA (128ng/mL vs. 45ng/mL, 8μgMuV-Prl vs. 8μgMuV, p<0.05). Serum IgG isotypes and splenocyte cytokine secretion induced by MuV-Prl suggested a predominant T helper cell (Th)1-type immune response. This response was characterized by: (1) ≥four-fold increase of IgG2a levels compared to IgG1; and (2) high IL-2 (644pg/mL)/IFN-γ (228pg/mL) and low IL-5 (31pg/mL) secretion in MuV-restimulated splenocytes from animals receiving MuV-Prl formulations. MuV-Prl vaccination induced higher levels of serum antibodies capable of neutralizing MuV in vitro than MuV alone, particularly for high-dose 8μg formulations (357 neutralizing units (NU)/mL vs. 32NU/mL, 8μgMuV-Prl vs. 8μgMuV, p<0.001). Thus, nasal MuV-Prl vaccines are fairly well-tolerated and highly immunogenic in mice.
Vaccine.Vaccine.2013 Nov 17. pii: S0264-410X(13)01531-4. doi: 10.1016/j.vaccine.2013.11.014. [Epub ahead of print]
An inactivated, mucosal mumps virus (MuV) vaccine would address many of the problems associated with current live-attenuated formulations. Protollin (Prl)-based adjuvants (containing TLR2 and TLR4 ligands) are well-suited for nasal administration. We sought to develop an inactivated whole-virus nasa
PMID 24252699

Japanese Journal

小児同種造血細胞移植経験者に対する弱毒化生ワクチン接種の安全性と有効性の検討

青木孝浩,康勝好,川野豊,久保田泰央,大山亮,森麻希子,荒川ゆうき,林真由美,花田良二
日本造血細胞移植学会雑誌 3(3), 86-92, 2014
… 彼らへのvaccine preventable diseases（VPD）の対応が望まれている一方で，造血細胞移植後の生ワクチン接種に対する安全性と有効性に対する報告は限られている。 …
NAID 130004596542

Novel polyvalent live vaccine against varicella-zoster and mumps virus infections

Matsuura Masaaki,Somboonthum Pranee,Murakami Kouki [他]
Microbiology and immunology 57(10), 704-714, 2013-10
NAID 40019842436

免疫抑制薬内服中の腎疾患患者への弱毒生ワクチン接種の有効性と安全性についての検討

亀井宏一,宮園明典,佐藤舞,石川智朗,藤丸拓也,小椋雅夫,伊藤秀一
日本小児腎臓病学会雑誌 24(2), 179-186, 2011
　免疫抑制薬内服患者への生ワクチン接種は添付文書上では禁忌とされている。しかしながら，免疫抑制薬内服患者はウイルス感染症で致命的となるリスクが高く，接種が望ましいという意見もあり，予防接種ガイドラインでは禁忌にはなっていない。今回われわれは，免疫抑制薬内服中で，麻疹・風疹・水痘・おたふくかぜについて酵素抗体法で (－) か (±) を示した腎疾患または膠原病患者に，当院倫理委員会承認後に患者毎に十 …
NAID 130002114184